Study: Radionuclide-based therapy shows promise for CVD

05/23/2013 | Healio

Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs could allow for the treatment of inflammation in the atherosclerotic plaques associated with cardiovascular disease, according to a study presented at a nuclear cardiology conference. PET/CT scans showed that treatment with lutetium-177 DOTATATE can lead to significant reductions in vessel absorption of the ligand, the study said. "Our results should act as a stimulus for further exploration of radionuclide-based interventions in atherosclerosis," said researcher Imke Schatka from the Hannover Medical School in Germany.

View Full Article in:

Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ